专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2008134445A3 PLATELET ACTIVATION RECEPTOR CLEC-2: COMPOSITIONS AND USES THEREOF 审中-公开
标题翻译： PLATELET激活受体CLEC-2：其组合物及其用途
公开(公告)号：WO2008134445A3
公开(公告)日：2009-04-30
申请号：PCT/US2008061446
申请日：2008-04-24
申请人： UNIV YAMANASHI , OZAKI YUKIO , SUZUKI-INOUE KATSUE , KATO YUKINARI
发明人： OZAKI YUKIO , SUZUKI-INOUE KATSUE , KATO YUKINARI
IPC分类号： A61K39/395 , A61P7/02 , A61P9/04 , A61P9/10
CPC分类号： C07K14/7056 , A61K38/00 , C07K2319/30
摘要： Disclosed are compositions comprising the platelet activation receptor C-type Lectin- like Receptor 2 (CLEC-2), and compositions comprising anti-CLEC-2 antibodies or antibodies that inhibit the interaction of CLEC-2 with podoplanin. Also disclosed are and methods of treating subjects in need thereof, comprising administering to the subject an effective amount of the disclosed compositions. Disclosed are recombinant CLEC-2 polypeptides, nucleic acids, antibodies, and compositions comprising recombinant CLEC-2 polypeptides, nucleic acids and antibodies. CLEC-2, has been found to interact with podoplanin. Recombinant CLEC-2 inhibits platelet aggregation induced by podoplanin- expressing tumor cells or lymphatic endothelial cells. Thus, CLEC-2 is responsible for platelet aggregation induced by endogenously expressed podoplanin on cell surfaces. CLEC- 2 is therefore a physiological target protein of podoplanin and is involved in podoplanin- induced platelet aggregation, tumor metastasis, and other cellular responses related to podoplanin. Disclosed are methods of treating, for instance, platelet aggregation-related disorders by administering effective amounts of the disclosed compositions to subjects in need thereof.
摘要翻译：公开了包含血小板活化受体C型凝集素样受体2（CLEC-2）的组合物和包含抗CLEC-2抗体或抑制CLEC-2与podoplanin的相互作用的抗体的组合物。还公开了治疗有此需要的受试者的方法和方法，其包括向受试者施用有效量的所公开的组合物。公开了重组CLEC-2多肽，核酸，抗体和包含重组CLEC-2多肽，核酸和抗体的组合物。已经发现CLEC-2与podoplanin相互作用。重组CLEC-2抑制由表达表达平滑蛋白的肿瘤细胞或淋巴内皮细胞诱导的血小板聚集。因此，CLEC-2负责细胞表面内源表达的podoplanin诱导的血小板聚集。因此，CLEC-2是podoplanin的生理目标蛋白，并且涉及podoplanin诱导的血小板聚集，肿瘤转移以及与podoplanin相关的其他细胞反应。公开了通过向有需要的受试者施用有效量的所公开的组合物来治疗例如血小板聚集相关疾病的方法。

2. 发明申请

WO2008134445A8 PLATELET ACTIVATION RECEPTOR CLEC-2: COMPOSITIONS AND USES THEREOF 审中-公开
标题翻译：血小板活化受体CLEC-2：组合物及其用途
公开(公告)号：WO2008134445A8
公开(公告)日：2009-07-30
申请号：PCT/US2008061446
申请日：2008-04-24
申请人： UNIV YAMANASHI , OZAKI YUKIO , SUZUKI-INOUE KATSUE , KATO YUKINARI
发明人： OZAKI YUKIO , SUZUKI-INOUE KATSUE , KATO YUKINARI
IPC分类号： A61K39/395 , A61P7/02 , A61P9/04 , A61P9/10
CPC分类号： C07K14/7056 , A61K38/00 , C07K2319/30
摘要： Disclosed are compositions comprising the platelet activation receptor C-type Lectin- like Receptor 2 (CLEC-2), and compositions comprising anti-CLEC-2 antibodies or antibodies that inhibit the interaction of CLEC-2 with podoplanin. Also disclosed are and methods of treating subjects in need thereof, comprising administering to the subject an effective amount of the disclosed compositions. Disclosed are recombinant CLEC-2 polypeptides, nucleic acids, antibodies, and compositions comprising recombinant CLEC-2 polypeptides, nucleic acids and antibodies. CLEC-2, has been found to interact with podoplanin. Recombinant CLEC-2 inhibits platelet aggregation induced by podoplanin- expressing tumor cells or lymphatic endothelial cells. Thus, CLEC-2 is responsible for platelet aggregation induced by endogenously expressed podoplanin on cell surfaces. CLEC- 2 is therefore a physiological target protein of podoplanin and is involved in podoplanin- induced platelet aggregation, tumor metastasis, and other cellular responses related to podoplanin. Disclosed are methods of treating, for instance, platelet aggregation-related disorders by administering effective amounts of the disclosed compositions to subjects in need thereof.
摘要翻译：公开了包含血小板活化受体C型凝集素样受体2（CLEC-2）的组合物，以及包含抑制CLEC-2与podoplanin相互作用的抗CLEC-2抗体或抗体的组合物。还公开了治疗有需要的受试者的方法和方法，包括向受试者施用有效量的公开的组合物。公开了包含重组CLEC-2多肽，核酸和抗体的重组CLEC-2多肽，核酸，抗体和组合物。已发现CLEC-2与podoplanin相互作用。重组CLEC-2抑制由表达podoplanin的肿瘤细胞或淋巴管内皮细胞诱导的血小板聚集。因此，CLEC-2负责内源性表达的podoplanin在细胞表面诱导的血小板聚集。因此，CLEC-2是podoplanin的生理靶蛋白并且参与podoplanin诱导的血小板聚集，肿瘤转移以及与podoplanin相关的其他细胞应答。公开了通过将有效量的公开组合物给予有需要的受试者来治疗例如血小板聚集相关障碍的方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式